Published in N Engl J Med on June 19, 1980
Prostaglandin synthesis by rat glomerular mesangial cells in culture. Effects of angiotensin II and arginine vasopressin. J Clin Invest (1983) 1.44
Role of the kidney in congestive heart failure. Relationship of cardiac index to kidney function. Drugs (1990) 1.43
Responses of plasma concentrations of A type natriuretic peptide and B type natriuretic peptide to alacepril, an angiotensin-converting enzyme inhibitor, in patients with congestive heart failure. Br Heart J (1994) 1.30
Renin-angiotensin inhibition in systolic heart failure and chronic kidney disease. Am J Med (2012) 1.22
Cardiac sympathetic afferent reflexes in heart failure. Heart Fail Rev (2000) 1.18
Haemodynamic, hormonal, and electrolyte effects of enalapril in heart failure. Br Heart J (1983) 1.07
Transient renal dysfunction during initial inhibition of converting enzyme in congestive heart failure. Br Heart J (1984) 1.04
Renin-angiotensin inhibition in diastolic heart failure and chronic kidney disease. Am J Med (2013) 1.03
Enalapril: a review of human pharmacology. Drugs (1985) 1.02
Reversible renal failure after combined treatment with enalapril and frusemide in a patient with congestive heart failure. Br Heart J (1986) 0.98
Effect of captopril on renal function in patients with congestive heart failure. Br Heart J (1981) 0.98
Endocrine mechanisms in congestive cardiac failure. Renin, aldosterone and atrial natriuretic hormone. Drugs (1986) 0.94
Acute and long-term effects of captopril on exercise cardiac performance and exercise capacity in congestive heart failure. Br J Clin Pharmacol (1982) 0.93
Factors influencing survival and mode of death in severe chronic ischaemic cardiac failure. Br Heart J (1987) 0.90
Haemodynamic and myocardial metabolic effects of captopril in chronic heart failure. Br Heart J (1982) 0.89
Controlled trial of enalapril in congestive cardiac failure. Br Heart J (1985) 0.87
Cellular mechanisms mediating rat renal microvascular constriction by angiotensin II. J Clin Invest (1997) 0.85
Haemodynamic effects of dobutamine in patients with congestive heart failure receiving captopril. Br Heart J (1981) 0.84
Effects of captopril on membrane current and contraction in single ventricular myocytes from guinea-pig. Br J Pharmacol (1991) 0.82
Effects of enalapril in systolic heart failure patients with and without chronic kidney disease: insights from the SOLVD Treatment trial. Int J Cardiol (2012) 0.80
Effects of enalapril on clinical status, biochemistry, exercise performance and haemodynamics in heart failure. Drugs (1985) 0.79
Effects of repeated doses of enalapril on renal function in man. Br J Clin Pharmacol (1985) 0.79
Regional circulatory response to converting-enzyme inhibition in congestive heart failure. Br J Clin Pharmacol (1982) 0.78
Haemodynamic and neurohumoral response to exercise in patients with congestive heart failure treated with captopril. Br Heart J (1985) 0.77
Renal Denervation Therapy for the Treatment of Arrhythmias: Is the Sky the Limit? J Am Heart Assoc (2017) 0.77
Endocrine physiology of electrolyte metabolism. Drugs (1984) 0.76
Aspects of molecular biology and biochemistry of the cardiac renin-angiotensin system. Br J Clin Pharmacol (1989) 0.76
Angiotensin converting enzyme inhibition: a new therapeutic modality. Bull N Y Acad Med (1981) 0.76
Which vasodilator drug in patients with chronic heart failure? A randomised comparison of captopril and hydralazine. Br J Clin Pharmacol (1991) 0.75
Acute and chronic effects of captopril therapy in patients with refractory heart failure. Br J Clin Pharmacol (1982) 0.75
The renal effects of dopamine and dobutamine in stable chronic heart failure. Postgrad Med J (1993) 0.75
Clinical and haemodynamic effects of low dose captopril in severe chronic heart failure. Br J Clin Pharmacol (1982) 0.75
Angiotensin converting enzyme inhibition and cerebral circulation--a review. Br J Clin Pharmacol (1989) 0.75
A comparison of the chronic effects of oral xamoterol and enalapril on blood pressure and renal function in mild to moderate heart failure. Br J Clin Pharmacol (1991) 0.75
Short and long-term effects of treatment with low dose captopril in patients with severe congestive heart failure. Br J Clin Pharmacol (1982) 0.75
Answers to complex questions cannot be derived from 'simple' trials. Br Heart J (1993) 0.75
Characterization of cardiac angiotensin converting enzyme (ACE) and in vivo inhibition following oral quinapril to rats. Br J Pharmacol (1990) 0.75
Sustained haemodynamic and clinical effects of captopril in long-term treatment of severe chronic congestive heart failure. Br J Clin Pharmacol (1982) 0.75
Long-term treatment of congestive heart failure with captopril. Br J Clin Pharmacol (1982) 0.75
Recent advances in cardiology. Postgrad Med J (1982) 0.75
The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. U.S. Carvedilol Heart Failure Study Group. N Engl J Med (1996) 12.77
Genetic mapping of a gene causing hypertension in the stroke-prone spontaneously hypertensive rat. Cell (1991) 9.99
The effects of antihypertensive therapy on the quality of life. N Engl J Med (1986) 5.32
Quality of life and antihypertensive therapy in men. A comparison of captopril with enalapril. The Quality-of-Life Hypertension Study Group. N Engl J Med (1993) 4.62
The emerging concept of vascular remodeling. N Engl J Med (1994) 4.27
Double-blind, placebo-controlled study of the effects of carvedilol in patients with moderate to severe heart failure. The PRECISE Trial. Prospective Randomized Evaluation of Carvedilol on Symptoms and Exercise. Circulation (1996) 3.98
Captopril-induced functional renal insufficiency in patients with bilateral renal-artery stenoses or renal-artery stenosis in a solitary kidney. N Engl J Med (1983) 3.63
Characterization of human prorenin expressed in mammalian cells from cloned cDNA. Proc Natl Acad Sci U S A (1986) 3.60
High-throughput genotyping with single nucleotide polymorphisms. Genome Res (2001) 3.55
Race and the response to adrenergic blockade with carvedilol in patients with chronic heart failure. N Engl J Med (2001) 3.44
Discontinuation of antihyperlipidemic drugs--do rates reported in clinical trials reflect rates in primary care settings? N Engl J Med (1995) 3.29
Cardiac-specific expression of heme oxygenase-1 protects against ischemia and reperfusion injury in transgenic mice. Circ Res (2001) 2.98
Norepinephrine stimulates apoptosis in adult rat ventricular myocytes by activation of the beta-adrenergic pathway. Circulation (1998) 2.91
Concurrent morning increase in platelet aggregability and the risk of myocardial infarction and sudden cardiac death. N Engl J Med (1987) 2.83
Impaired vasodilation of forearm resistance vessels in hypercholesterolemic humans. J Clin Invest (1990) 2.69
Association of angiotensinogen gene T235 variant with increased risk of coronary heart disease. Lancet (1995) 2.52
Behavioural and cardiovascular effects of disrupting the angiotensin II type-2 receptor in mice. Nature (1995) 2.51
Opposing effects of beta(1)- and beta(2)-adrenergic receptors on cardiac myocyte apoptosis : role of a pertussis toxin-sensitive G protein. Circulation (1999) 2.50
Minichromosome maintenance proteins as biological markers of dysplasia and malignancy. Clin Cancer Res (1999) 2.49
Nitric oxide synthase: role in the genesis of vascular disease. Annu Rev Med (1997) 2.44
Renal failure in the patient with cirrhosis. The role of active vasoconstriction. Am J Med (1970) 2.43
Interleukin-1beta and tumor necrosis factor-alpha decrease collagen synthesis and increase matrix metalloproteinase activity in cardiac fibroblasts in vitro. Circ Res (2000) 2.36
L-arginine improves endothelium-dependent vasodilation in hypercholesterolemic humans. J Clin Invest (1992) 2.35
DNA replication licensing and human cell proliferation. J Cell Sci (2001) 2.30
In situ hybridization evidence for angiotensinogen messenger RNA in the rat proximal tubule. An hypothesis for the intrarenal renin angiotensin system. J Clin Invest (1990) 2.29
Oxidative stress regulates collagen synthesis and matrix metalloproteinase activity in cardiac fibroblasts. Am J Physiol Cell Physiol (2001) 2.28
Assessment of autonomic regulation in chronic congestive heart failure by heart rate spectral analysis. Am J Cardiol (1988) 2.25
Reciprocal feedback regulation of kidney angiotensinogen and renin mRNA expressions by angiotensin II. Am J Physiol (1992) 2.20
Gene therapy inhibiting neointimal vascular lesion: in vivo transfer of endothelial cell nitric oxide synthase gene. Proc Natl Acad Sci U S A (1995) 2.14
Vascular smooth muscle cell hypertrophy vs. hyperplasia. Autocrine transforming growth factor-beta 1 expression determines growth response to angiotensin II. J Clin Invest (1992) 2.13
A genetic linkage map of the laboratory rat, Rattus norvegicus. Nat Genet (1995) 2.10
Induction of platelet-derived growth factor A-chain and c-myc gene expressions by angiotensin II in cultured rat vascular smooth muscle cells. J Clin Invest (1989) 2.10
Spontaneous recurrent hypothermia accompanying agenesis of the corpus callosum. Brain (1969) 2.10
Increased rat cardiac angiotensin converting enzyme activity and mRNA expression in pressure overload left ventricular hypertrophy. Effects on coronary resistance, contractility, and relaxation. J Clin Invest (1990) 2.07
Functional significance of presynaptic alpha-adrenergic receptors in failing and nonfailing human left ventricle. Circulation (1995) 2.00
Report of the National Heart, Lung, and Blood Institute Special Emphasis Panel on Heart Failure Research. Circulation (1997) 2.00
Reactive oxygen species mediate amplitude-dependent hypertrophic and apoptotic responses to mechanical stretch in cardiac myocytes. Circ Res (2001) 1.97
Decreased lymphocyte beta-adrenergic-receptor density in patients with heart failure and tolerance to the beta-adrenergic agonist pirbuterol. N Engl J Med (1981) 1.97
Nitric oxide, atrial natriuretic peptide, and cyclic GMP inhibit the growth-promoting effects of norepinephrine in cardiac myocytes and fibroblasts. J Clin Invest (1998) 1.96
Cdc6 protein causes premature entry into S phase in a mammalian cell-free system. EMBO J (1998) 1.95
Single intraluminal delivery of antisense cdc2 kinase and proliferating-cell nuclear antigen oligonucleotides results in chronic inhibition of neointimal hyperplasia. Proc Natl Acad Sci U S A (1993) 1.94
Relation of the renin-angiotensin-aldosterone system to clinical state in congestive heart failure. Circulation (1981) 1.90
Expression cloning of type 2 angiotensin II receptor reveals a unique class of seven-transmembrane receptors. J Biol Chem (1993) 1.87
Further defining housekeeping, or "maintenance," genes Focus on "A compendium of gene expression in normal human tissues". Physiol Genomics (2001) 1.85
Accentuated vascular and endocrine response to SQ 20881 in hypertension. N Engl J Med (1977) 1.83
The angiotensin II type 2 (AT2) receptor antagonizes the growth effects of the AT1 receptor: gain-of-function study using gene transfer. Proc Natl Acad Sci U S A (1995) 1.82
Flow activates an endothelial potassium channel to release an endogenous nitrovasodilator. J Clin Invest (1991) 1.82
Thy-1, a novel marker for angiogenesis upregulated by inflammatory cytokines. Circ Res (1998) 1.81
Right ventricular ejection fraction: an indicator of increased mortality in patients with congestive heart failure associated with coronary artery disease. J Am Coll Cardiol (1983) 1.81
Modulation of cardiac autonomic activity during and immediately after exercise. Am J Physiol (1989) 1.81
Tissue angiotensin system in cardiovascular medicine. A paradigm shift? Circulation (1994) 1.79
Sodium regulation of angiotensinogen mRNA expression in rat kidney cortex and medulla. J Clin Invest (1986) 1.79
Overexpression of angiotensin AT1 receptor transgene in the mouse myocardium produces a lethal phenotype associated with myocyte hyperplasia and heart block. Proc Natl Acad Sci U S A (1997) 1.78
Captopril-induced changes in prostaglandin production: relationship to vascular responses in normal man. J Clin Invest (1980) 1.76
Regulation of vascular endothelial growth factor in cardiac myocytes. Circ Res (1995) 1.75
Fluid shear stress induces endothelial transforming growth factor beta-1 transcription and production. Modulation by potassium channel blockade. J Clin Invest (1995) 1.71
A gene therapy strategy using a transcription factor decoy of the E2F binding site inhibits smooth muscle proliferation in vivo. Proc Natl Acad Sci U S A (1995) 1.71
Mice lacking inducible nitric oxide synthase have improved left ventricular contractile function and reduced apoptotic cell death late after myocardial infarction. Circ Res (2001) 1.70
Acute endothelin A receptor blockade causes selective pulmonary vasodilation in patients with chronic heart failure. Circulation (2000) 1.69
New positive inotropic agents in the treatment of congestive heart failure. Mechanisms of action and recent clinical developments. 2. N Engl J Med (1986) 1.69
Multiple autocrine growth factors modulate vascular smooth muscle cell growth response to angiotensin II. J Clin Invest (1993) 1.66
Double antibody radioimmunoassay of renin activity and angiotensin II in human peripheral plasma. J Lab Clin Med (1973) 1.65
Altered adrenal sensitivity to angiotensin II in low-renin essential hypertension. Hypertension (1999) 1.64
Acute hemodynamic and clinical effects of levosimendan in patients with severe heart failure. Study Investigators. Circulation (2000) 1.63
The simultaneous measurement of aldosterone, cortisol, and corticosterone in human peripheral plasma by displacement analysis. J Lab Clin Med (1972) 1.62
Angiotensin II type 2 receptor mediates programmed cell death. Proc Natl Acad Sci U S A (1996) 1.61
Recent progress in angiotensin II type 2 receptor research in the cardiovascular system. Hypertension (1999) 1.60
Reciprocal influence of salt intake on adrenal glomerulosa and renal vascular responses to angiotensin II in normal man. J Clin Invest (1974) 1.59
Exaggerated left ventricular dilation and reduced collagen deposition after myocardial infarction in mice lacking osteopontin. Circ Res (2001) 1.56
L-arginine augments endothelium-dependent vasodilation in cholesterol-fed rabbits. Circ Res (1990) 1.55
Long-term sequential changes in exercise capacity and chronotropic responsiveness after cardiac transplantation. Circulation (1997) 1.54
Therapeutic applications of transcription factor decoy oligonucleotides. J Clin Invest (2000) 1.53
Ex-vivo gene therapy of human vascular bypass grafts with E2F decoy: the PREVENT single-centre, randomised, controlled trial. Lancet (1999) 1.53
Adrenergic regulation of cardiac myocyte apoptosis. J Cell Physiol (2001) 1.52
Intracellular trafficking of angiotensin II and its AT1 and AT2 receptors: evidence for selective sorting of receptor and ligand. Mol Endocrinol (1997) 1.52
Increased accumulation of tissue ACE in human atherosclerotic coronary artery disease. Circulation (1996) 1.51
The renin-angiotensin-aldosterone system: a specific target for hypertension management. Am J Hypertens (1999) 1.51
Familial hypo-beta-lipoproteinemia: a genetic disorder of lipid metabolism with nervous system involvement. Am J Med (1969) 1.51
Aldosterone: a mediator of myocardial necrosis and renal arteriopathy. Endocrinology (2000) 1.50
Prostaglandins in severe congestive heart failure. Relation to activation of the renin--angiotensin system and hyponatremia. N Engl J Med (1984) 1.49
Effects of myocardial alpha 1-adrenergic receptor stimulation and blockade on contractility in humans. Circulation (1991) 1.48
Intimal hyperplasia after vascular injury is inhibited by antisense cdk 2 kinase oligonucleotides. J Clin Invest (1994) 1.48
Cell cycle progression: new therapeutic target for vascular proliferative disease. Circulation (1998) 1.46
Impaired potassium-stimulated aldosterone production: a possible explanation for normokalemic glucocorticoid-remediable aldosteronism. J Clin Endocrinol Metab (1997) 1.46
Influence of inhaled nitric oxide on systemic flow and ventricular filling pressure in patients receiving mechanical circulatory assistance. Circulation (1997) 1.45
Tissue-specific activation of cardiac angiotensin converting enzyme in experimental heart failure. Circ Res (1991) 1.43
Blood pressure response to angiotensin II, low-density lipoprotein cholesterol and polymorphisms of the angiotensin II type 1 receptor gene in hypertensive sibling pairs. J Mol Med (Berl) (2001) 1.43
Secondary pulmonary hypertension in chronic heart failure: the role of the endothelium in pathophysiology and management. Circulation (2000) 1.43
Senescence and the renal vasculature in normal man. Circ Res (1974) 1.43